SCHEMBL2034010

SCHEMBL2034010

CC(Sc1ncc(C(F)(F)F)cc1Cl)c1ccnc(N)n1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.43
ALDH1A1 P00352 5/20 0.40
KDM4E B2RXH2 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
POLB P06746 2/20 0.40
HPGD P15428 3/20 0.40
NPSR1 Q6W5P4 3/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
GAA P10253 2/20 0.40
CYP1A2 P05177 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP3A4 P08684 1/20 0.39
MAPT P10636 1/20 0.39
HRH4 Q9H3N8 1/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2035177 0.75 HRH4 (0.43) ALDH1A1KDM4EPOLBHPGDNPSR1
SCHEMBL2035178 0.75 HRH4 (0.43) ALDH1A1KDM4EPOLBHPGDNPSR1
SCHEMBL2033840 0.74 POLB (0.41) ALDH1A1POLBCYP1A2CYP2C19CYP3A4
SCHEMBL18780239 0.73 PKM (0.56) PKMALDH1A1KDM4ESMN1; SMN2NPSR1
SCHEMBL2037546 0.71 POLB (0.72) POLBHRH4
SCHEMBL2037543 0.71 POLB (0.72) POLBHRH4
SCHEMBL2051616 0.70 POLB (0.47) ALDH1A1KDM4ESMN1; SMN2POLBHPGD
SCHEMBL2051615 0.70 POLB (0.47) ALDH1A1KDM4ESMN1; SMN2POLBHPGD
SCHEMBL2037516 0.68 POLB (0.61) POLBHRH4
SCHEMBL2037517 0.68 POLB (0.61) POLBHRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2516397-B1 Amino-heteroaryl derivatives as HCN blockers MERCK SHARP & DOHME (NL) 2016-07-13 EP claimed
EP-2516397-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS MSD Oss B.V. (NL) 2012-10-31 EP claimed
WO-2011076723-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS N.V. ORGANON (NL) 2011-06-30 WO claimed
EP-2516397-B1 Amino-heteroaryl derivatives as HCN blockers MERCK SHARP & DOHME (NL) 2016-07-13 EP disclosed
US-8952001-B2 Amino-heteroaryl derivatives as HCN blockers MERCK SHARP & DOHME CORP. (US) 2015-02-10 US disclosed
EP-2516397-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS MSD Oss B.V. (NL) 2012-10-31 EP disclosed
US-20120264728-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-10-18 US disclosed
WO-2011076723-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS N.V. ORGANON (NL) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264728-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS HCN1, HCN3, HCN2 PKM 2201/4885ALDH1A1 1694/4885KDM4E 3696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.